Cargando…

Close relationship of PAI-1 (plasminogen activator inhibitor-1) with multiple organ dysfunction syndrome and abnormal glucose metabolism investigated by means of artificial pancreas

Detalles Bibliográficos
Autores principales:	Hoshino, M, Haraguchi, Y, Sakai, M, Saegusa, H, Hayashi, K, Horita , N, Ohsawa, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 1998
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3301265/ http://dx.doi.org/10.1186/cc153

Ejemplares similares

Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas
por: Hoshino, Masami, et al.
Publicado: (2001)

tPA-PAl (tissue plasminogen activator—plasminogen activator inhibitor-1 complex) can be a predictive marker of multiple organ dysfunction syndrome in seriously ill acute patients with glucose intolerance — analysis under strict blood glucose control by artificial pancreas
por: Hoshino, M, et al.
Publicado: (1999)

Investigation of insulin clearance in septic patients with glucose intolerance: analysis under strict blood glucose control by means of artificial pancreas
por: Hoshino, M, et al.
Publicado: (2001)

Investigation of the factors which influence insulin sensitivity in septic patients with glucose intolerance: analysis with glucose clamp method by means of artificial pancreas
por: Hoshino, M, et al.
Publicado: (2002)

Hypercoagulability indicated by elevated blood TFPI (tissue factor pathway inhibitor) levels is closely related to severity of septic patients with glucose intolerance
por: Hoshino, M, et al.
Publicado: (2000)

Influence of insulin clearance to glucose tolerance in acutely ill severe patients: analysis with glucose clamp method by means of artificial pancreas
por: Hoshino, M, et al.
Publicado: (2003)

Evaluation of glucose intolerance in acutely ill severe patients by means of an artificial pancreas
por: Hoshino, M, et al.
Publicado: (2004)

Changes in plasminogen activator inhibitor-1 (PAI-1) in patients with severe sepsis or septic shock
por: Ikeda, T, et al.
Publicado: (2002)

Investigation of the blood glucose target for mortality reduction by means of bedside-type artificial pancreas
por: Hoshino, M, et al.
Publicado: (2011)

Predictive role of plasminogen-activator-inhibitor-1 (PAI-1) in non-ST-segment elevation acute coronary syndrome
por: Sinkovic, A, et al.
Publicado: (2002)

PAI-1, the Plasminogen System, and Skeletal Muscle
por: Rahman, Fasih Ahmad, et al.
Publicado: (2020)

Investigation of insulin clearance in severely acutely ill patients with glucose intolerance evaluated by means of bedside-type artificial pancreas
por: Hoshino, M, et al.
Publicado: (2007)

Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
por: Alotaibi, Fahad T., et al.
Publicado: (2019)

Influence of blood glucose-related factors to glucose tolerance in acutely ill severe patients evaluated by means of bedside-type artificial pancreas
por: Hoshino, M, et al.
Publicado: (2005)

Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population
por: White, Marquitta J., et al.
Publicado: (2015)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Relationship between blood glucose level and outcome in acutely ill severe patients with glucose intolerance evaluated by means of a bedside-type artificial pancreas
por: Hoshino, M, et al.
Publicado: (2006)

Significance of the suppression of blood glucose variability in acutely ill severe patients with glucose intolerance evaluated by means of bedside-type artificial pancreas
por: Hoshino, M, et al.
Publicado: (2008)

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
por: Pierga, J. Y., et al.
Publicado: (1997)

Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
por: Party, Hélène, et al.
Publicado: (2019)

Criteria and Search for Specific Assays for Active Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma
por: Kluft, C.
Publicado: (2000)

Increased expression of urokinase type plasminogen activator(u-PA), plasminogen activator inhibitor-1(PAI-1), and collagenases in Caco-2 cells infected by Salmonella typhimurium.
por: Park, C. G., et al.
Publicado: (1997)

Gastric Expression of Plasminogen Activator Inhibitor (PAI)-1 Is Associated with Hyperphagia and Obesity in Mice
por: Kenny, Susan, et al.
Publicado: (2013)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix
Publicado: (1991)

Role of 4G/5G plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and the PAI-1 plasma levels in the outcome of patients with severe sepsis
por: Lorente, L, et al.
Publicado: (2009)

Plasminogen activator inhibitor (PAI)-1 suppresses inhibition of gastric emptying by cholecystokinin (CCK) in mice()
por: Gamble, Joanne, et al.
Publicado: (2013)

Fibronectin, Plasminogen Activator Inhibitor Type 1 (PAI-1) And Uterine Artery Doppler Velocimetry as Markers of Preeclampsia
por: Bodova, Kristina Biskupska, et al.
Publicado: (2011)

Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women
por: Ozgen, Merih, et al.
Publicado: (2012)

PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent
por: Hohensinner, Philipp J., et al.
Publicado: (2017)

Association of Polymorphisms in Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), and Renin (REN) with Recurrent Pregnancy Loss in Korean Women
por: Cho, Hee Young, et al.
Publicado: (2021)

Glucocorticoid-Responsive Tissue Plasminogen Activator (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-Related Psychiatric Disorders
por: Mennesson, Marie, et al.
Publicado: (2023)

PSUN171 CORRELATIONS BETWEEN SERUM AND TEAR PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) AND TISSUE PLASMINOGEN ACTIVATOR (tPA) IN PATIENTS WITH DIABETIC RETINOPATHY
por: Jasmiad, Nurbadriah, et al.
Publicado: (2022)

Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells
por: Roy, Ananya, et al.
Publicado: (2015)

Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms
por: Doyle, Francis J., et al.
Publicado: (2014)

Automated closed-loop control of diabetes: the artificial pancreas
por: Kovatchev, Boris
Publicado: (2018)

An overview of advancements in closed-loop artificial pancreas system
por: Dermawan, Doni, et al.
Publicado: (2022)

Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells
Publicado: (1987)

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
por: Witte, J H de, et al.
Publicado: (1999)

Serum plasminogen activator inhibitor 1 (PAI-1) and intra-ocular pressure (IOP): the Guangzhou biobank cohort study
por: Heggie, J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cob6r9jsh9mgjg9a72s2vvbv2e